BIIB111 ( DrugBank: - )


1 disease
IDDisease name (Link within this page)Number of trials
90Retinitis pigmentosa1

90. Retinitis pigmentosa


Clinical trials : 147 Drugs : 176 - (DrugBank : 43) / Drug target genes : 49 - Drug target pathways : 110
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT03584165
(ClinicalTrials.gov)
June 4, 201829/6/2018Long-term Safety and Efficacy Follow-up of BIIB111 for the Treatment of Choroideremia and BIIB112 for the Treatment of X-Linked Retinitis PigmentosaA Long-term Follow-up Study to Evaluate the Safety and Efficacy of Retinal Gene Therapy in Subjects With Choroideremia Previously Treated With Adeno-Associated Viral Vector Encoding Rab Escort Protein-1 (AAV2-REP1) and in Subjects With X-Linked Retinitis Pigmentosa Previously Treated With Adeno-Associated Viral Vector Encoding RPGR (AAV8-RPGR) in an Antecedent StudyChoroideremia;X-Linked Retinitis PigmentosaGenetic: BIIB111;Genetic: BIIB112NightstaRx Ltd, a Biogen CompanyNULLEnrolling by invitation10 YearsN/AMale440Phase 3United States;Brazil;Canada;Denmark;Finland;France;Germany;Netherlands;United Kingdom